Trial Profile

A clinical study of edaravone to identify and measure the specific biomarkers in people with amyotrophic lateral sclerosis (ALS)

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 May 2019 Planned number of patients changed from 200 to 300, according to a Mitsubishi Tanabe Pharma America media release.
03 May 2019 According to a Mitsubishi Tanabe Pharma America media release, Oxford BioDynamics has join this ALS Biomarker Study.
28 Mar 2019 According to a Mitsubishi Tanabe Pharma America media release, the company has collaborated with the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) for the conduct of this study. The first biomarker study patient is anticipated to be enrolled late spring of 2019, with early interim analyses planned for later in the year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com